Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Medpace Holdings Q3 2026 Results: Net Income $137M, Up 23.7% YoY

Medpace reported net income of $137.5 million for the third quarter of 2026, up from $111.1 million in the prior year period, driven by an 8.5% increase in net revenue to $716.0 million. For the nine months ended September 30, 2026, net cash provided by operating activities remained strong at $530.4 million, while the company continued its share repurchase program, spending $294.8 million year-to-date.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue716.0659.9
Profit before tax170.9142.8
Net income137.5111.1
EPS (diluted, $ a share)$4.84$3.86

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+23.7%
Revenue, year on year+8.5%
Operating margin23.1%
Source

10-Q filed with the SEC, NASDAQ: MEDP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Medpace Holdings, Inc.: key numbers

Share price
$648.20Close, Nov 16
Market cap
$18.1B
Shares outstanding
27.97MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Medpace Holdings, Inc.

All →
6:25 PM ET Form 4
Insider Selling

Medpace Holdings General Counsel & Corp. Secy. Stephen P. Ewald Sells $859K of Stock

Stephen P. Ewald, General Counsel & Corp. Secy., sold 1,245 shares of Medpace Holdings, Inc. at $690.00 a share, worth $859K in total on Oct 29, 2026. Shares held after the trade: 19,098 (-6.1%).

Value
$859K
Shares
1,245
Price
$690.00
Role
General Counsel & Corp. Secy.
Holding change
-6.1%
Trade date
Oct 29, 2026
4:23 PM ET Form 4
Insider Selling

Medpace Holdings Exec. VP, Operations Susan E. Burwig Sells $13.5M of Stock

Susan E. Burwig, Exec. VP, Operations, sold 20,000 shares of Medpace Holdings, Inc. at $677.00 a share, worth $13.5M in total between Oct 26, 2026 and Oct 27, 2026. Shares held after the trade: 54,012 (-6.8%).

Value
$13.5M
Shares
20,000
Average price
$677.00
Role
Exec. VP, Operations
Holding change
-6.8%
Trade date
Oct 26, 2026 to Oct 27, 2026
4:17 PM ET 8-K
Financial Results

Medpace Holdings Financial Results

Medpace reported Q3 2026 revenue of $716.0 million, an 8.5% increase year-over-year, and GAAP net income of $137.5 million ($4.84 per diluted share). Alongside the results, the Board authorized a new $1.0 billion stock repurchase program effective through December 2028, replacing the previous authorization which had $527.0 million remaining.

5:43 PM ET Form 4
Insider Selling

Medpace Holdings President & CEO August J. Troendle Sells $30.3M of Stock

August J. Troendle, President & CEO, sold 48,667 shares of Medpace Holdings, Inc. at $621.02 to $625.47 a share (average $623.03) in 2 transactions, worth $30.3M in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 338,225 (-6.1%).

Value
$30.3M
Shares
48,667
Average price
$623.03
Role
President & CEO
Holding change
-6.1%
Trade date
Sep 29, 2026 to Sep 30, 2026
4:25 PM ET Form 4
Insider Selling

Medpace Holdings President & CEO August J. Troendle Sells $6.75M of Stock

August J. Troendle, President & CEO, sold 10,880 shares of Medpace Holdings, Inc. at $620.40 a share, worth $6.75M in total on Sep 17, 2026. Shares held after the trade: 504,273 (-2.1%).

Value
$6.75M
Shares
10,880
Price
$620.40
Role
President & CEO
Holding change
-2.1%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.